Eisai Co., Ltd.

OTCPK:ESAL.Y Voorraadrapport

Marktkapitalisatie: US$17.7b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Eisai Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Belangrijke informatie

1.1%

Groei van de winst

1.0%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie6.0%
Inkomstengroei5.1%
Rendement op eigen vermogen3.6%
Nettomarge4.3%
Volgende winstupdate06 Feb 2023

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe Eisai geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

OTCPK:ESAL.Y Opbrengsten, kosten en inkomsten (JPY Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 22752,50032,233382,752173,324
30 Jun 22741,59432,690374,428168,422
31 Mar 22756,22647,954356,847171,738
31 Dec 21712,93557,311317,150165,418
30 Sep 21691,25062,508293,153162,699
30 Jun 21679,25359,855282,369161,584
31 Mar 21645,94242,119272,568150,299
31 Dec 20707,88893,682271,476145,248
30 Sep 20713,400120,571261,973139,628
30 Jun 20707,203124,523253,516141,217
31 Mar 20695,621121,767248,554140,116
31 Dec 19661,64696,659244,091146,367
30 Sep 19631,97457,725239,503147,863
30 Jun 19643,53172,747233,180140,143
31 Mar 19642,83463,386223,798144,844
31 Dec 18627,36763,714212,469139,100
30 Sep 18625,10665,679195,229138,461
30 Jun 18611,49954,347186,198140,514
31 Mar 18600,05451,845179,915139,579
31 Dec 17569,81429,048178,312134,955
30 Sep 17554,27630,269178,090123,639
30 Jun 17544,02729,425176,249119,503
31 Mar 17539,09739,358175,633112,478
31 Dec 16530,69655,031175,240110,471
30 Sep 16542,31371,812178,825114,420
30 Jun 16545,60269,227182,036115,750
31 Mar 16547,92254,933188,227122,307

Kwaliteitswinsten: ESAL.Y has a large one-off gain of ¥13.4B impacting its September 30 2022 financial results.

Groeiende winstmarge: ESAL.Y's current net profit margins (4.3%) are lower than last year (9%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: ESAL.Y's earnings have grown by 1.1% per year over the past 5 years.

Versnelling van de groei: ESAL.Y's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Winst versus industrie: ESAL.Y had negative earnings growth (-48.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (7%).

Rendement op eigen vermogen

Hoge ROE: ESAL.Y's Return on Equity (3.6%) is considered low.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y